BIZWIRETV
21.10.2016 14:10:38 CEST | Business Wire | Press release
On the latest BizWireTV , new technology from Smartmatic is giving us a glimpse of what voting might be like in the future: online and verified with a selfie.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161021005134/en/
Now you can watch BizWireTV , and the latest breakthroughs in tech from the biggest brands on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices.
Watch the full episode for more stories including Whole Sale Jet Club, Misfit, Amazon and more on BizWireTV – featuring the Top Five Most-Shared Stories of the Week.
Catch the weekly series that showcases the hottest news stories published over Business Wire’s distribution network.
Sponsored Headline:
360insights Raises $30 Million to Fuel Global Growth of Channel Success Platform
Top of the Wire:
Smartmatic offers new tech that verifies online voting with a selfie
The Launch Pad:
Wholesale Jet Club brands itself as the “Costco” of the private jet industry
ecobee launches new ecobee3 lite smart thermostat
Misfit releases the new Misfit Phase Hybrid smartwatch
The GRAMMY Museum presents The Taylor Swift Experience at the Seaport District
And the Top 5 Most Shared Stories of the Week:
Warner Bros. and the LEGO Group launch the LEGO Harry Potter Collection
RegTech firm ComplyAdvantage raises $8.2M in Series A funding
Amazon creates 120,000 seasonal jobs in customer fulfillment and customer service (NASDAQ:AMZN)
Garth Brooks is now streaming, for the first time, exclusively on Amazon Music (NASDAQ:AMZN)
Virgin cruises set sail under new moniker “Virgin Voyages”
A core component of the video programming is news-related data analysis powered by Business Wire’s NewsTrak reports and NUVI social media tracking. BizWireTV is hosted by Erin Ade . Watch for new episodes each Friday available on BizWireTV’s new home on Tempo .
The weekly schedule for BizWireTV episodes:
BizWireTV: Friday
at 6:00am
BizWireTV Accelerator Report: Sunday at 3:00pm
Click here to share BizWireTV’s latest episode on Twitter: http://ctt.ec/1c7bZ
About Business Wire:
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure . Investor relations, public relations, public policy and marketing professionals rely on Business Wire to accurately distribute market-moving news and multimedia, host online newsrooms and IR websites , build content marketing platforms , generate social engagements and provide audience analysis that improves interaction with specified target markets. Founded in 1961, Business Wire is a trusted source for news organizations, journalists, investment professionals and regulatory authorities, delivering news directly into editorial systems and leading online news sources via its multi-patented simultaneous NX Network. Business Wire has 29 offices worldwide to securely meet the varying needs of communications professionals and news consumers. In 2015, Business Wire teamed up with Al Roker Entertainment to create BizWireTV, a bi-weekly digital video news program that features the top trending news releases that cross the wire.
Learn more at services.BusinessWire.com and Tempo , the Business Wire resource for industry trends; follow updates on Twitter: @businesswire or on Facebook .
Click here to subscribe to Mobile Alerts for Business Wire.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161021005134/en/
Contact:
Business Wire
Scott Fedonchik, +1-212-752-9600
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom